This result seems independent on the MPM subtypes (Table 2) given that IL7 expression was similar in epithelioid mesothelioma (EM), sarcomatoid mesothelioma (SM), biphasic mesothelioma (BM), and diffuse malignant mesothelioma (DM) (Fig. S8A) and that the prognostic value of IL7 expression was also confirmed in EM patients (Fig. S8B). The gene discussed is IL7; the disease is systemic mastocytosis.